SG11201705344VA - Methods of transdifferentiation and methods of use thereof - Google Patents

Methods of transdifferentiation and methods of use thereof

Info

Publication number
SG11201705344VA
SG11201705344VA SG11201705344VA SG11201705344VA SG11201705344VA SG 11201705344V A SG11201705344V A SG 11201705344VA SG 11201705344V A SG11201705344V A SG 11201705344VA SG 11201705344V A SG11201705344V A SG 11201705344VA SG 11201705344V A SG11201705344V A SG 11201705344VA
Authority
SG
Singapore
Prior art keywords
methods
transdifferentiation
Prior art date
Application number
SG11201705344VA
Other languages
English (en)
Inventor
Sarah Ferber
Original Assignee
Orgenesis Ltd
Tel Hashomer-Medical Res Infrastructure And Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orgenesis Ltd, Tel Hashomer-Medical Res Infrastructure And Services Ltd filed Critical Orgenesis Ltd
Publication of SG11201705344VA publication Critical patent/SG11201705344VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
SG11201705344VA 2014-12-30 2015-12-30 Methods of transdifferentiation and methods of use thereof SG11201705344VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098050P 2014-12-30 2014-12-30
PCT/IL2015/051267 WO2016108237A1 (fr) 2014-12-30 2015-12-30 Procédés de transdifférenciation et procédés d'utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
SG11201705344VA true SG11201705344VA (en) 2017-07-28

Family

ID=56284403

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201705344VA SG11201705344VA (en) 2014-12-30 2015-12-30 Methods of transdifferentiation and methods of use thereof

Country Status (15)

Country Link
US (3) US10179151B2 (fr)
EP (2) EP3240576B1 (fr)
JP (1) JP6817943B2 (fr)
KR (1) KR102487883B1 (fr)
CN (1) CN107750170B (fr)
AU (1) AU2015373129B2 (fr)
BR (1) BR112017014280A2 (fr)
CA (1) CA2972569A1 (fr)
CO (1) CO2017006937A2 (fr)
EA (1) EA035360B1 (fr)
IL (1) IL253234B (fr)
MA (1) MA41296A (fr)
MX (1) MX2017008669A (fr)
SG (1) SG11201705344VA (fr)
WO (1) WO2016108237A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207578A2 (fr) 2013-06-13 2014-12-31 Orgenesis Ltd. Populations cellulaires, procédés de transdifférenciation et leurs procédés d'utilisation
JP6749239B2 (ja) 2013-09-24 2020-09-02 ガイナー ライフ サイエンシズ，インク． 細胞インプラントのガス処理用システム
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
CA3023221A1 (fr) 2016-05-05 2017-11-09 Southwest Research Institute Bioreacteur tridimensionnel pour expansion cellulaire et applications associees
CN110167613B (zh) 2016-11-15 2022-01-11 吉纳生命科学公司 适合用于皮下植入物的经皮气体扩散装置
CA3062412A1 (fr) 2017-05-04 2018-11-08 Giner Life Sciences, Inc. Dispositif implantable de distribution robuste, de gaz et procedes, systemes et dispositifs l'utilisant
WO2018207179A1 (fr) 2017-05-08 2018-11-15 Orgenesis Ltd. Populations de cellules transdifférenciées et leurs procédés d'utilisation
CN110944653A (zh) * 2017-05-29 2020-03-31 奥尔吉尼西丝有限公司 用于提供细胞替代疗法的组合物和方法
JP2020537522A (ja) 2017-10-13 2020-12-24 イーエムベーアー−インスティテュート フュール モレクラレ バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 体細胞の増強された再プログラミング
US20210171915A1 (en) * 2018-03-06 2021-06-10 Orgenesis Inc. Three dimensional clusters of transdifferentiated cells, compositions and methods thereof
US11149244B2 (en) 2018-04-04 2021-10-19 Southwest Research Institute Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy
SG11202102986XA (en) 2018-09-24 2021-04-29 Southwest Res Inst Three-dimensional bioreactors
EP3816276A1 (fr) * 2019-10-31 2021-05-05 Unicyte Islet AG Structures de cellules de type îlots pancréatiques viables et leur procédé de préparation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0264166B1 (fr) 1986-04-09 1996-08-21 Genzyme Corporation Animaux transformés génétiquement sécrétant une protéine désirée dans le lait
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4992417A (en) 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5427940A (en) 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE69435026D1 (de) 1993-08-16 2007-10-31 Res Dev Foundation Ein homeobox-faktor der insulin-expression in pankreatischen inselnzellen stimuliert
US5858973A (en) 1994-02-23 1999-01-12 The General Hospital Corporation Transcription factor and uses therefor
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
ATE321880T1 (de) 1995-11-30 2006-04-15 Res Dev Foundation Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren
IL118376A0 (en) 1996-05-22 1996-09-12 Univ Ben Gurion Polysaccharide sponges for cell culture and transplantation
JP2000513227A (ja) 1996-06-24 2000-10-10 ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド インスリン分泌細胞の単離および増殖方法
US6114113A (en) 1997-08-11 2000-09-05 Chiron Corporation High efficiency genetic modification method
CA2221195A1 (fr) 1997-11-14 1999-05-14 Chantal E. Holy Matrice en polymere biodegradable
US6143293A (en) 1998-03-26 2000-11-07 Carnegie Mellon Assembled scaffolds for three dimensional cell culturing and tissue generation
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6242666B1 (en) 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US6774120B1 (en) 1999-06-01 2004-08-10 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US8778899B2 (en) 1999-06-01 2014-07-15 Sarah Ferber Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
US6759039B2 (en) 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
US7214371B1 (en) 2000-09-01 2007-05-08 Ben-Gurion University Of The Negev Research & Development Authority Tissue engineered biografts for repair of damaged myocardium
US7524492B2 (en) 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
CA2463914A1 (fr) 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Transformation de cellules souches et progenitrices du foie en cellules fonctionnelles du pancreas
US7722894B2 (en) 2001-10-22 2010-05-25 Massachusetts Institute Of Technology Biodegradable polymer
IL162131A0 (en) 2001-12-07 2005-11-20 Geron Corp Islet cells from human embryonic stem cells
AU2003217658A1 (en) * 2002-02-22 2003-09-09 University Of Florida Cellular trans-differentiation
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
JP4136434B2 (ja) 2002-04-17 2008-08-20 進 清野 インスリン産生細胞の誘導
US20060122104A1 (en) 2002-05-28 2006-06-08 Presnell Sharon C Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
ES2440654T3 (es) 2003-05-05 2014-01-29 Ben-Gurion University Of The Negev Research And Development Authority Preparaciones poliméricas reticuladas inyectables y usos de las mismas
JP2006525994A (ja) * 2003-05-12 2006-11-16 サラ ファーバー， 非膵島組織における調節された膵ホルモンの産生を誘導する方法
EP1649000A4 (fr) 2003-06-30 2008-04-30 Lifescan Inc Ensemencement de cellules pancreatiques sur des matrices poreuses
US20060205072A1 (en) 2003-08-27 2006-09-14 Nobuko Uchida Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
CA2548464C (fr) 2003-12-09 2013-02-12 Ben-Gurion University Of The Negev Research And Development Authority Bioreacteur a perfusion a milieu d'impulsion avec moyen de transport de masse ameliore pour constructions cellulaires 3d multiples
US20090239298A1 (en) 2004-08-25 2009-09-24 Technion Research & Development Foundation Ltd. Methods of generating embryoid bodies using three dimensional scaffolds
US8679484B2 (en) 2005-03-02 2014-03-25 Polyrizon Ltd. Method for removal of toxins from mucosal membranes
EP1856246B1 (fr) 2005-03-07 2015-07-15 Technion Research & Development Foundation Limited Matrice naturelle decellularisee derivee d'un tissu et procedes permettant de generer et d'utiliser celle-ci
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
CN101553245A (zh) * 2006-07-19 2009-10-07 佛罗里达大学研究基金会有限公司 用于细胞重编程的组合物及其用途
AU2007335753B2 (en) 2006-12-18 2013-12-05 Ben Gurion University Of The Negev Scaffolding for tissue regeneration or repair
US20100226976A1 (en) 2007-07-11 2010-09-09 Marcelle Machluf Encapsulated mesenchymal stem cells and uses thereof
IL187707A0 (en) 2007-11-27 2008-11-03 Univ Ben Gurion Alginate scaffold in hepatectomy
WO2009126927A2 (fr) * 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Procédés de génération de cellules produisant de l'insuline
WO2010022395A2 (fr) * 2008-08-22 2010-02-25 President And Fellows Of Harvard College Procédés de reprogrammation de cellules
WO2011016423A1 (fr) 2009-08-02 2011-02-10 学校法人 東京女子医科大学 Feuillet de cellules de langerhans, procédé de production associé, et application associée
KR101874463B1 (ko) * 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
JP2011223993A (ja) 2010-03-30 2011-11-10 Kumamoto Univ 幹細胞の分化誘導方法
EP2580320B1 (fr) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogrammation de cellules pour leur conférer un nouveau destin
WO2013021389A2 (fr) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Régulation à la baisse de mir-7 pour favoriser la différenciation des cellules bêta et la production d'insuline
US9731046B2 (en) 2012-02-21 2017-08-15 Ben Gurion University Of The Negev Research And Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
WO2014102801A1 (fr) 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Utilisation de compositions d'alginate en prévention ou réduction d'une atteinte hépatique provoquée par un agent hépatotoxique
PL2994528T3 (pl) 2013-05-08 2024-04-22 Prokidney Organoidy zawierające wyizolowane komórki nerkowe oraz ich zastosowania
WO2014207578A2 (fr) 2013-06-13 2014-12-31 Orgenesis Ltd. Populations cellulaires, procédés de transdifférenciation et leurs procédés d'utilisation
WO2015125147A1 (fr) 2014-02-20 2015-08-27 B. G. Negev Technologies And Applications Ltd Polyplexes anioniques destinés à être utilisés pour l'administration d'acides nucléiques
WO2015184313A1 (fr) 2014-05-30 2015-12-03 Secant Medical, Inc. Préparations de matériaux polymères à médiation par l'eau
WO2015186127A1 (fr) 2014-06-02 2015-12-10 B. G. Negev Technologies And Applications Ltd Modification régiosélective de polysaccharides et applications associées
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3400074B1 (fr) 2016-01-07 2021-10-20 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Compositions pour générer des réponses immunotolérantes
US20170290954A1 (en) 2016-04-07 2017-10-12 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Compositions and methods for treating spinal cord injury
WO2017175229A1 (fr) 2016-04-07 2017-10-12 B.G. Negev Technologies And Applications Ltd. Compositions de polysaccharides et leurs utilisations
WO2018207179A1 (fr) 2017-05-08 2018-11-15 Orgenesis Ltd. Populations de cellules transdifférenciées et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CN107750170A (zh) 2018-03-02
CO2017006937A2 (es) 2017-10-20
IL253234A0 (en) 2017-08-31
CA2972569A1 (fr) 2016-07-07
EP3698803B1 (fr) 2023-03-08
CN107750170B (zh) 2021-10-08
US11617769B2 (en) 2023-04-04
MA41296A (fr) 2017-11-07
EP3240576B1 (fr) 2020-03-04
WO2016108237A1 (fr) 2016-07-07
EA035360B1 (ru) 2020-06-02
US10179151B2 (en) 2019-01-15
US20200297777A1 (en) 2020-09-24
BR112017014280A2 (pt) 2018-03-27
KR20170102308A (ko) 2017-09-08
EA201791508A1 (ru) 2018-05-31
AU2015373129B2 (en) 2021-07-15
US20160220616A1 (en) 2016-08-04
AU2015373129A1 (en) 2017-08-03
IL253234B (en) 2020-04-30
EP3698803A1 (fr) 2020-08-26
MX2017008669A (es) 2018-02-16
JP2018502574A (ja) 2018-02-01
EP3240576A4 (fr) 2018-06-20
US20190134097A1 (en) 2019-05-09
KR102487883B1 (ko) 2023-01-11
US10668107B2 (en) 2020-06-02
JP6817943B2 (ja) 2021-01-20
EP3240576A1 (fr) 2017-11-08

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL276946A (en) Antiproliferative compounds and methods of use
IL250415B (en) Antibodies against pd-l and methods of using them
IL278574B1 (en) Compounds acting on glycans and methods of using them
IL253234A0 (en) Methods for transdifferentiation and methods to use them
FI3548033T3 (fi) Yhdisteitä ja menetelmiä niiden käyttämiseksi
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
GB201421847D0 (en) Dispensers and methods of use thereof
HRP20190432T1 (hr) Spojevi pladienolid piridina i postupci uporabe
GB201417048D0 (en) Occupancy-control device and methods of use
LT3089971T (lt) Junginiai ir panaudojimo būdai
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
HK1243404A1 (zh) 色酰胺組合物和使用方法
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof